



Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events

October 31, 2024

BASKING RIDGE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that management will participate at the following events in November:

BIO-Europe (November 4-6, 2024; Virtual: November 12-13, 2024)

Format: In-person/Virtual

Location: Stockholm, Sweden

Lisata representative: Tariq Imam, Vice President of Business Development and Operations and Corporate Counsel at Lisata

Mr. Imam will be participating in one-on-one meetings at this event. If interested in meeting, please send a meeting request through the online partnering platform. For more information on BIO-Europe and how to register, please [click here](#) or contact EBDcustomerservice@ebdgroup.com.

PEGS Europe Summit (November 5-7, 2024)

Format: In-person

Location: Barcelona, Spain

Presentation Date: Tuesday, November 5, 2024

Presentation Time: 3:20 p.m. CEST

Presenter: David J. Mazzo, PhD, President and Chief Executive Officer at Lisata

For more information on PEGS Europe and how to register, please [click here](#).

LSX Inv€stival showcase 2024 (November 18, 2024)

Format: In-person

Location: Tobacco Dock, UK

Presentation Date: Monday, November 18, 2024

Presentation Time: 1:00 p.m. GMT

Presenter: David J. Mazzo, PhD, President and Chief Executive Officer of Lisata

For more information on the LD Micro Main Event and how to register, please [click here](#) or contact steph@lsxleaders.com.

About Lisata Therapeutics

Lisata Therapeutics is a [clinical-stage pharmaceutical company](#) dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata's internalizing RGD, or Arginylglycylaspartic acid, (iRGD) cyclic peptide product candidate, [certepetide](#), is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Lisata has already established noteworthy commercial and R&D partnerships based on its [CendR Platform® technology](#). The Company expects to announce numerous milestones over the next 1.5 years and believes that its projected capital will fund operations into early 2026, encompassing anticipated data milestones from its ongoing and planned clinical trials. Learn more about [certepetide's mechanism of action in our short film](#). For more information on the Company, please visit www.lisata.com.

Contact:

Investors:

Lisata Therapeutics, Inc.

John Menditto

Vice President, Investor Relations and Corporate Communications

Phone: 908-842-0084

Email: jmenditto@lisata.com

Media:

ICR Healthcare

Elizabeth Coleman

Senior Associate

Phone: 203-682-4783

Email: elizabeth.coleman@westwicke.com